Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - Taylor & Francis
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

[HTML][HTML] Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - ncbi.nlm.nih.gov
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - search.proquest.com
Purpose: Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - europepmc.org
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - dovepress.com
Purpose: Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Kedox-responsive and pH-sensitive nanoparticies enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - go.gale.com
Purpose: Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo

S Tan, G Wang - Drug design, development and therapy, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.

S Tan, G Wang - Drug Design, Development and Therapy, 2017 - europepmc.org
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …